Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Upcoming Presentations at the Society for Inherited Metabolic Disorders Annual Meeting and The International Liver Congress™ (EASL)
March 27, 2019 08:15 ET | Kaleido Biosciences
Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia LEXINGTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) --...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Initiation of Dosing in Non-IND Clinical Studies in Patients with Urea Cycle Disorders and Cirrhosis
March 21, 2019 08:00 ET | Kaleido Biosciences
Studies are evaluating novel Microbiome Metabolic Therapies, KB195 and KB174, in target patient populations; data expected in Q4 2019 Third non-IND clinical study in healthy subjects also underway to...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Highlight its Platform to Identify and Evaluate Microbiome Metabolic Therapies to Reduce Gut Ammonia Production in Presentation at Keystone Symposia on Microbiome
March 08, 2019 08:30 ET | Kaleido Biosciences
LEXINGTON, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Closing of Initial Public Offering
March 04, 2019 16:15 ET | Kaleido Biosciences
LEXINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Pricing of Initial Public Offering
February 27, 2019 19:27 ET | Kaleido Biosciences
LEXINGTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...